|
|
Home > Investor Relations > Financials
> P & L Account
> Ranbaxy Laboratories Limited - Consolidated (US GAAP) |
| |
P & L
Account
Untitled Document
CONSOLIDATED STATEMENTS
OF INCOME
(All amounts in Rupees Million, unless otherwise stated) |
| |
Year
ended December 31, |
| |
2006 |
2005 |
| Revenues |
|
|
| Product sales |
60,275.71 |
50,468.67 |
| Service income |
406.47 |
273.75 |
| Other operating revenue |
738.11 |
856.11 |
| |
61,420.29 |
51,598.53 |
| Cost of
sales (excluding depreciation and amortization) |
29,465.74 |
27,143.85 |
| Gross profit |
31,954.55 |
24,454.68 |
| Operating expenses |
|
|
| Selling, general
and administrative expenses |
19,651.83 |
17,274.06 |
| Research and development
expenses |
3,982.42 |
5,055.33 |
| Depreciation and
amortization |
2,894.31 |
1,718.00 |
| Foreign exchange (gain) /
loss |
(682.06) |
978.98 |
| Total operating expenses |
25,846.50 |
25,026.37 |
| Operating income /
(loss) |
6,108.05 |
(571.69) |
| Equity in gain of affiliate |
50.30 |
4.71 |
| Interest expense |
(1,789.20) |
(669.60) |
| Interest income |
207.05 |
173.99 |
| Other income |
431.28 |
300.49 |
| Income / (loss) from
continuing operations before income taxes, discontinued operations
and minority interest |
5,007.48 |
(762.10) |
| Income tax expense / (benefit)
on continuing operations |
889.58 |
(1,020.91) |
| Income from continuing
operations before discontinued operation and minority interest |
4,117.90 |
258.81 |
| Minority interest |
(57.31) |
(26.38) |
| Income from continuing
operations |
4,060.59 |
232.43 |
| Gain on disposal of discontinued
operations, net of tax |
- |
161.88 |
| Income from discontinued operations,
net of tax |
- |
384.72 |
| Net income |
4,060.59 |
779.03 |
| Earnings per equity
share |
|
|
| Basic |
|
|
| Continuing operations |
Rs.
10.90 |
Rs.
0.62 |
| Discontinued operations |
– |
Rs.
1.47 |
| Net income |
Rs. 10.90 |
Rs. 2.09 |
| Diluted |
|
|
| Continuing operations |
Rs.
10.88 |
Rs. 0.62 |
| Discontinued operations |
– |
Rs. 1.47 |
| Net income |
Rs.
10.88 |
Rs. 2.09 |
Weighted average number of equity
shares used in
computing earnings per equity share |
|
|
| Basic |
372,595,730 |
372,216,805 |
| Effect of dilutive securities-employee
stock option |
746,412 |
1,089,479 |
| Diluted |
373,342,142 |
373,306,284 |
| The accompanying notes are
an integral part of these consolidated financial statements. |
|
|
|